Infectious complications in chronic lymphocytic leukaemia

Hematology and Cell Therapy

Volumn 41, Issue 4, 1999, Pages 145-151

  Morra, E ^a   Nosari, A ^a   Montillo, M ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Hypogammaglobulinemia; Immunodeficiency; Infections; Purine analogues

Indexed keywords

ANTINEOPLASTIC AGENT; PURINE DERIVATIVE;

BACTERIAL INFECTION; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; HUMAN; HYPOGAMMAGLOBULINEMIA; IMMUNE DEFICIENCY; INFECTION PREVENTION; INFECTION RISK; INFECTION SENSITIVITY; MALE; REVIEW; RISK FACTOR; T LYMPHOCYTE;

ANIMALS; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; OPPORTUNISTIC INFECTIONS; PURINES; RISK FACTORS;

EID: 0032886463     PISSN: 12693286     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00282-999-0145-0     Document Type: Review

References (55)

1. Anaissie EJ, Kontoyannis D, O' Brien S et al. (1998) Infections in patients with chronic lymphocytic leukemia treated with Flurarabine. Ann Intern Med 129: 559-566
2. Apostopoulos A, Simeonidis A, Zoumbos N (1990) Prognostic significance of immune function parameters in patients with chronic lymphocytic leukemia. Eur J Haematol 44: 39-44
3. Bartik, MM, Welker D, Kay NE (1998) Impairments in immune cell function in B cell chronic lymphocytic leukemia. Semin Oncol 25: 27-33
4. Beck OL (1981) Distribution of virus antibody activity among human IgG subclasses. Clin Exp Immunol 43: 626-632
5. Bergmann L, Fenchel K, Jahn B et al. (1993) Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann Oncol 4:371-375
6. Bernard CH, Mombelli G. Klastersky J. (1981) Pneumococcal bacteriemia in patients with neoplastic disease. Eur J Cancer Clin Oncol 17: 1041-1046
7. Bezares RF, Murro HH, Diaz AF, Saidon G (1997) Prevention of infectious events with Immunoglobulin A (IgA) nebulisations in patients with chronic lymphoproliferative disorders treated with purine analogues. Hematol Cell Ther 39: S83
8. Briggs PG, Kraft N, Atkins RC (1990) T cells and CD45 expression in B-chronic lymphocytic leukemia. Leukemia Res 14: 155-159
9. Bunch C (1987) Managment of infection in chronic lymphocytic leukemia. In: Gale RP, Kai KR (eds) Chronic lymphocytic leukemia: recent prognosis, future advances. Liss, New York, pp 373-381
10. Catovsky D, Lauria F, Matutes E, et al. (1981) Increased T lymphocytes in B-cell chronic lymphocytic leukemia. Br J Haematol 47: 539-544
11. Chapel HM, Bunch C (1987) Mechanisms of infection in chronic lymphocytic leukemia. Semin Hematol 24: 291-296
12. Chapel H, Dicato M, Gamm H, et al. (1994) Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimens. Br J Haematol 88: 209-212
13. Cheson BD (1995) Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 13: 2431-2448
14. Chu M, Brown AE, Blevins A, et al. (1983) Severe pneumococcal infection in patients with neoplastic disease. Cancer 51: 1546-1550
15. Cone L, Uhr JW (1964) Immunological deficiency disorders associated with chronic lymphocytic leukemia and multiple myeloma. J Clin Invest 43: 2241-2248
16. Delpero JR, Mouvenaeghe G, Gastan JA, et al. (1990) Splenectomy for hypersplenism in chronic lymphocytic leukemia and malignant non-Hodgkin's lymphoma. Br J Surg 77:443-450
17. Dighiero G (1993) Hypogammaglobulinemia and disordered immunity in CLL. In: Cheson BD (ed) Chronic lymphocytic leukemia. Scientific advances and clinical developments. Dekker, New York, pp 147-166
18. Foa R, Lauria F, Lusso P, et al. (1984) Discrepancy between phenotypic and functional features of natural killer T-lymphocytes in B-cell chronic lymphocytic leukemia. Br J Haematol 58: 509-516
19. French Cooperative Group on CLL (1994) Comparison of Fludarabine (FDB), CAP and CHOP in previously untreated stage B and C chronic lymphocytic leukemia (CLL). First interim results of a randomized clinical trial in 247 patients (abstract). Blood 83 [Suppl 1]:461a
20. French Cooperative Group on CLL, Johnson S, Smith AG, Loffler H et al. (1996) Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced stage chronic lymphocytic leukemia. Lancet 347: 1432-1438
21. Gribabis DA, Pangalis GA, Boussiotis VA, Hannoun C (1992) Influenza vaccine in B- chronic lymphocytic leukemia patients. Blood 80 [Suppl 1]: 48a
22. Hansen MM (1973) Chronic lymphocytic leukaemia: clinical studies based on 189 cases followed for a long time. Scand J Haematol 18 [Suppl]: 1-282
23. Heath M, Cheson BD (1985) Defective complement activity in chronic lymphocytic leukemia. Am J Haematol 19: 63-73
24. Hudson RP, Wilson SJ (1960) Hypogammaglobulinemia and chronic lymphocytic leukemia. Cancer 13: 200-204
25. Jacobson DR, Ballard HS, Silber R, et al. (1988) Antibody response in pneumococcal immunization in patients with chronic lymphocytic leukemia. Blood 72 [Suppl 1]: 205a
26. Juliusson G (1997) Complications in the treatment of CLL with purine analogues. Hematol Cell Ther 39: S41-S44
27. Itälä M, Helenius H, Nikoskelaien J, Remes K (1992) Infections and serum IgG levels in patients with chronic lymphocytic leukemia. Eur J Haematol 48: 266-270
28. Kai N (1981) Abnormal T-cell subpopulation function in CLL: excessive suppressor (Tγ) and deficient (Tμ) activity with respect to B-cell proliferation. Blood 57: 418-420
29. Kai N, Perri RT (1988) Immunobiology of malignant B cells and immunoregolatory cells in B-chronic lymphocytic leukemia. Clin Lab Med 8: 163-177
30. Kaplan MH, Rosen PP, Armstrong D (1977) Cryptococcosis in cancer hospital. Cancer 39: 2265-2274
31. Kauffman C, Israel K, Smith J, et al. (1978) Histoplasmosis in immunosuppressed patients. Am J Med 64: 923-932
32. Keating MJ (1990) Fludarabine phosphate in the treatment of chronic lymphocytic leukemia. Semin Oncol 17: 49-62
33. Keating MJ, O'Brien S, Kantarjian H, et al (1993) Long term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 81: 2878-2884
34. Keating M, O'Brien S, Lerner S, et al. (1998) Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimen as initial therapy. Blood 92: 1165-1171
35. Kontoyanis DP, Anaissie EJ, Bodey GP (1993) Infection in chronic lymphocytic leukemia: a reappraisal. In: Cheson BD (ed) Chronic lymphocytic leukemia. Scientific Advances and Clinical Developments. Dekker, New York, pp 399-417
36. Larson DA, Tomlinson LJ (1953) Quantitative antibody studies in man, III: antibody response in leukemia and other malignant lymphomata. J Clin Invest 32: 317-321
37. Mayo J W, Wenzel RP (1982) Rates of hospital acquired blood-stream infections in patients with specific malignancy. Cancer 50: 187-190
38. Molica S (1994) Infections in chronic lymphocytic leukemia: risk factors and impact on survival and treatment. Leuk Lymphoma 13: 203-214
39. Montillo M, Tedeschi A, Orlandi E, et al (1997) Infectious events in indolent lymphoproliferative disorders treated with regimens including Fludarabine. Blood 90: 195a
40. Montserrat-Costa E, Matutes E, Rozman C, et al (1977) Infecciones en la leucemia linfoide cronica. SNGRA (Sangre) 22: 968-975
41. Morris PJ, Cooper IA, Madigan JP (1986) Splenectomy for hematological cytopenias in patients with malignant lymphomas. Lancet 2: 250-253
42. Morrison VA (1998) The infectious complications in chronic lymphocytic leukemia. Sem Oncol 25: 98-106
43. O' Brien S, Kantarjian H, Beran M, et al (1993) Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 82: 1695-1700
44. O' Brien S, Kantarjian H, Beran M et al. (1997) Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia 11: 1631-1635
45. Rai KR, Peterson B, Elias L, et al. (1996) A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia. A CALGB, SWOG, CTG/NCI and ECOG inter-group study. Blood 88: 141a
46. Robertson TI (1990) Complications and causes of death in B-cell chronic lymphocytic leukemia. Aust NZ J Med 20: 44-50
47. Ross SC, Densen P (1984) Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in immune deficiency. Medicine (Baltimore) 63: 243-273
48. Rozman C, Montserrat E, Vinolas N (1988) Serum immunoglobulins in B-CLL. Natural history and prognostic significance. Cancer 61: 279-283
49. Schlesinger M, Broman I, Lugassy G (1996) The complement system is defective in chronic lymphatic leukemia patients and in their healthy relatives. Leukemia 10: 1509-1513
50. Shaw RK, Szwed C, Boggs DR, et al. (1960) Infection and immunity in chronic lymphocytic leukemia. Arch Intern Med 106: 467-478
51. Travade PH, Dusart JD, Cavaroe D, et al. (1986) Les infections graves associees a la leucemie lymphoide chronique. Presse Med 15: 1715-1718
52. Twomey JT (1973) Infections complicating multiple myeloma and chronic lymphocytic leukemia. Arch Intern Med 132: 562-565
53. Ultmann JE, Fish W, Osserman E, et al. (1959) Clinical implications of hypogammaglobulinemia in patients with chronic lymphocytic leukemia and lymphocytic lymphosarcoma. Ann Int Med 51: 501-516
54. Zaknoen SL, Kay NE (1990) Immunoregulatory cell dysfunction in chronic B-cell leukemias. Blood Rev 4: 165-174
55. Zeya HI, Keku E, Richards F, et al. (1979) Monocyte and granulocyte defects in chronic lymphocytic leukemia. Am J Pathol 95: 43-54